Characterizing very and extremely preterm infants who received excess erythrocyte transfusions
Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respect to HAS 2014 Recommendations
Centre Hospitalier Universitaire, Amiens · NCT06909487
This study looks at very and extremely preterm infants who received extra blood transfusions to see how it affects their health and care in the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | N/A to 28 Days |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens (other) |
| Locations | 1 site (Amiens) |
| Trial ID | NCT06909487 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on very and extremely preterm infants who are at risk of severe anemia and require erythrocyte transfusions to maintain adequate hemoglobin levels. It aims to characterize the clinical outcomes of these infants in relation to the HAS 2014 recommendations for transfusion practices. The study will analyze data from infants hospitalized in intensive care at CHU Amiens-Picardie over a two-year period, assessing the benefits and risks associated with excess transfusions. By understanding the implications of transfusion practices, the study seeks to improve care for this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are premature newborns aged 28 days or younger, born at less than 31 weeks of gestation, and hospitalized in intensive care.
Not a fit: Patients who are not preterm or are older than 28 days of life will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved transfusion practices and better health outcomes for very and extremely preterm infants.
How similar studies have performed: While there have been studies on transfusion practices in preterm infants, this specific characterization approach in relation to the HAS recommendations is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age : ≤ 28 days of life * Premature newborn with term of birth \< 31 weeks hospitalized in intensive care or neonatology intensive care at CHU Amiens-Picardie (CHU-AP) between July 2022 and July 2024, whether born at CHU-AP maternity unit or transferred secondarily Exclusion Criteria: * Newborn with term of birth ≥ 31 weeks and \> 28 days of life
Where this trial is running
Amiens
- CHRU Amiens — Amiens, France (RECRUITING)
Study contacts
- Study coordinator: Guy KONGOLO, MD
- Email: kongolo.guy@chu-amiens.fr
- Phone: 33+322087601
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Very Preterm and Extremely Preterm Birth, Anemia, Erythrocyte Transfusion, Excess Transfusion, Very preterm and extremely preterm birth, Erythrocyte transfusion, excess transfusion